Elisah M Huynh, Mahmood Khan, Yanhan Ren, Anton Orlin, Szilard Kiss, Benjamin W Botsford
{"title":"多模态成像在去铁胺相关的眼部毒性：由于超治疗剂量的快速发展和尽管剂量减少进展。","authors":"Elisah M Huynh, Mahmood Khan, Yanhan Ren, Anton Orlin, Szilard Kiss, Benjamin W Botsford","doi":"10.1097/ICB.0000000000001746","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To characterize evolution of deferoxamine-related retinal toxicity in a patient exposed to supratherapeutic doses of deferoxamine and progression despite dose reduction and cessation.</p><p><strong>Methods: </strong>Observational clinical case Report.</p><p><strong>Results: </strong>A 59-year-old female with history of beta thalassemia requiring biweekly blood transfusions developed peripheral visual field loss and nyctalopia after taking supratherapeutic dosage of deferoxamine. She demonstrated progressive RPE thickening and photoreceptor loss despite reduction in dosage as she was unable to initially discontinue the medication, as vision decreased from 20/25 and 20/30 to 20/60 and 20/50. This report highlights the ocular toxicities linked with deferoxamine and examines whether dosage decrease reverses its effects.</p><p><strong>Conclusion: </strong>Deferoxamine use can precipitate RPE changes, thickening, and photoreceptor loss that can progress despite dose-reduction and cessation.</p>","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MULTIMODAL IMAGING IN DEFEROXAMINE-RELATED OCULAR TOXICITY: RAPID DEVELOPMENT DUE TO SUPRATHERPEUTIC DOSING AND PROGRESSION DESPITE DOSE REDUCTION.\",\"authors\":\"Elisah M Huynh, Mahmood Khan, Yanhan Ren, Anton Orlin, Szilard Kiss, Benjamin W Botsford\",\"doi\":\"10.1097/ICB.0000000000001746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To characterize evolution of deferoxamine-related retinal toxicity in a patient exposed to supratherapeutic doses of deferoxamine and progression despite dose reduction and cessation.</p><p><strong>Methods: </strong>Observational clinical case Report.</p><p><strong>Results: </strong>A 59-year-old female with history of beta thalassemia requiring biweekly blood transfusions developed peripheral visual field loss and nyctalopia after taking supratherapeutic dosage of deferoxamine. She demonstrated progressive RPE thickening and photoreceptor loss despite reduction in dosage as she was unable to initially discontinue the medication, as vision decreased from 20/25 and 20/30 to 20/60 and 20/50. This report highlights the ocular toxicities linked with deferoxamine and examines whether dosage decrease reverses its effects.</p><p><strong>Conclusion: </strong>Deferoxamine use can precipitate RPE changes, thickening, and photoreceptor loss that can progress despite dose-reduction and cessation.</p>\",\"PeriodicalId\":53580,\"journal\":{\"name\":\"Retinal Cases and Brief Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retinal Cases and Brief Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ICB.0000000000001746\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
MULTIMODAL IMAGING IN DEFEROXAMINE-RELATED OCULAR TOXICITY: RAPID DEVELOPMENT DUE TO SUPRATHERPEUTIC DOSING AND PROGRESSION DESPITE DOSE REDUCTION.
Purpose: To characterize evolution of deferoxamine-related retinal toxicity in a patient exposed to supratherapeutic doses of deferoxamine and progression despite dose reduction and cessation.
Methods: Observational clinical case Report.
Results: A 59-year-old female with history of beta thalassemia requiring biweekly blood transfusions developed peripheral visual field loss and nyctalopia after taking supratherapeutic dosage of deferoxamine. She demonstrated progressive RPE thickening and photoreceptor loss despite reduction in dosage as she was unable to initially discontinue the medication, as vision decreased from 20/25 and 20/30 to 20/60 and 20/50. This report highlights the ocular toxicities linked with deferoxamine and examines whether dosage decrease reverses its effects.
Conclusion: Deferoxamine use can precipitate RPE changes, thickening, and photoreceptor loss that can progress despite dose-reduction and cessation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
